1. Home
  2. GRDN vs STOK Comparison

GRDN vs STOK Comparison

Compare GRDN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardian Pharmacy Services Inc.

GRDN

Guardian Pharmacy Services Inc.

HOLD

Current Price

$33.54

Market Cap

2.1B

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$34.29

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRDN
STOK
Founded
2004
2014
Country
United States
United States
Employees
3400
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GRDN
STOK
Price
$33.54
$34.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
10
Target Price
$33.33
$34.50
AVG Volume (30 Days)
178.0K
512.5K
Earning Date
01-01-0001
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.67
EPS
N/A
0.85
Revenue
N/A
$36,555,000.00
Revenue This Year
$19.50
$430.19
Revenue Next Year
N/A
N/A
P/E Ratio
$117.77
$40.40
Revenue Growth
N/A
316.34
52 Week Low
$17.78
$5.35
52 Week High
$37.43
$38.62

Technical Indicators

Market Signals
Indicator
GRDN
STOK
Relative Strength Index (RSI) 52.10 60.72
Support Level $31.82 $30.68
Resistance Level $33.04 $34.67
Average True Range (ATR) 1.43 2.27
MACD -0.07 0.27
Stochastic Oscillator 52.93 92.67

Price Performance

Historical Comparison
GRDN
STOK

About GRDN Guardian Pharmacy Services Inc.

Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: